reports
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 ...
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3...
Universal Technical Institute Inc: 1 director
A director at Universal Technical Institute Inc sold 1,000,000 shares at 25.350USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
QNB Corp. Joins the OTCQX Market
QNB Corp. Joins the OTCQX Market Quakertown, PA, March 20, 2025 (GLOBE NEWSWIRE) -- QNB Corp. (the “Company” or “QNB”) (OTCQX: QNBC), the parent company of QNB Bank (the “Bank”), today announced it has qualified to trade on the OTCQX® Best Market. QNB Corp. upgraded to OTCQX from the Pink® market. QNB Corp. begins trading today on OTCQX under the symbol “QNBC.” Graduating to the OTCQX Market marks an important milestone for QNB Corp. in the U.S. public markets. The OTCQX Market enables QNB to maximize its value as a public company by providing transparent trading and easy access to...
Vistra Corp: 2 directors
Two Directors at Vistra Corp bought 1,548 shares at between 0.000USD and 126.750USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted stock units (RSUs) for 25,750 shares of Class A common stock to nine (9) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in...
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
SM SM ENERGY COMPANY
SIGI SELECTIVE INSURANCE GROUP INC.
PDFS PDF SOLUTIONS INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
ITCI INTRA-CELLULAR THERAPIES INC.
HII HUNTINGTON INGALLS INDUSTRIES INC.
FRPT FRESHPET INC
FFIN FIRST FINANCIAL BANKSHARES INC
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
CLRO CLEARONE
CINF CINCINNATI FINANCIAL CORPORATION
AKAM AKAMAI TECHNOLOGIES INC.
AFG AMERICAN FINANCIAL GROUP INC.
DGICA DONEGAL GROUP INC. CL A
CECE CECO ENVIRONMENTAL CORP.
OESX ORION ENERGY SYSTEMS INC.
NHC NATIONAL HEALTHCARE CORP.
PLBC PLUMAS BANCORP
JFR NUVEEN FLOATING RATE INCOME FUND
JELD JELD-WEN HOLDING INC.
CLF CLIFFS NATURAL RESOURCES INC.
VRNA VERONA PHARMA ADS
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
QNBC QNB CORP.
PCG PG &E CORPORATION
RCUS ARCUS BIOSCIENCES
REZI RESIDEO TECHNOLOGIES
CXDO INC.
CMTV CREXENDO
PRG COMMUNITY BANCORP INC. VT
VMEO PROG HOLDINGS
ETO INC.
ECAT VIMEO INC
MAIA EATON VANCE TAX ADV GBL DIV OPPTY
PFHC BLACKROCK ESG CAP ALLOCATION TR
ETG MAIA BIOTECHNOLOGY INC
EVT PROFRAC HLDG CORP
SSII EATON VANCE TAX ADV GLB DIN INC
ADVM EATON VANCE TAX ADVANTAGED DIVID IN
ISPO SS INNOVATIONS INTERNATIONAL INC
EVM ADVERUM BIOTECHNOLOGIES INC.
INSPIRATO INCORPORATED
EATON VANCE INSD CALIF MUN BD FD
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
SM SM ENERGY COMPANY
SIGI SELECTIVE INSURANCE GROUP INC.
PDFS PDF SOLUTIONS INC.
OXBR OXBRIDGE RE HOLDINGS
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
HMC HARMONIC
EL ESTEE LAUDER COMPANIES INC. CLASS A
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
BZH BEAZER HOMES USA INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
AKAM AKAMAI TECHNOLOGIES INC.
OLN OLIN CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
HP HELMERICH & PAYNE INC.
HI HILLENBRAND INC.
PLBC PLUMAS BANCORP
MRUS MERUS B V
QNBC QNB CORP.
MPB MID PENN BANCORP INC.
RCUS ARCUS BIOSCIENCES
EAF GRAFTECH INTERNATIONAL
AMCR AMCOR PLC
CXDO CREXENDO
IDYA IDEAYA BIOSCIENCES
MTCH MATCH GROUP INC.
IMNM IMMUNOME
PFX PHENIXFIN CORP
VMEO VIMEO INC
FLNC FLUENCE ENERGY INC
ECBK ECB BANCORP INC.
TLSI TRISALUS LIFE SCIENCES INC
TKO TKO GROUP HOLDINGS
SSII INC.
AEI SS INNOVATIONS INTERNATIONAL INC
OCX ALSET INC.
ISPO ONCOCYTE CORPORATION
INSPIRATO INCORPORATED
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial...
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update -- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH -- -- Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 --...
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Ca...
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. The management team will also participate in one-on-one in...
- Dylan Shindler
- Laura Chico
Vera Therapeutics Provides Business Update and Reports Fourth Quarter ...
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025Expanded atacicept clinical development program in multiple autoimmune kidney diseases proceeding in 2025Strengthened balance sheet to support clinical pipeline development, planned FDA submission, and potential 2026 commercial launch of atacicept for the treatment of IgAN BRIS...
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
PDFS PDF SOLUTIONS INC.
MTDR MATADOR RESOURCES COMPANY
FFIN FIRST FINANCIAL BANKSHARES INC
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
CINF CINCINNATI FINANCIAL CORPORATION
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
QNBC QNB CORP.
TXG 10X GENOMICS INC CLASS A
CMTV COMMUNITY BANCORP INC. VT
ECBK ECB BANCORP INC.
MAIA MAIA BIOTECHNOLOGY INC
ISPO INSPIRATO INCORPORATED
QNB Corp. Declares Q1 2025 Dividend
QNB Corp. Declares Q1 2025 Dividend Dividend payable on March 28, 2025 Quakertown, PA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of QNB Corp. (OTC Bulletin Board: QNBC), parent company of QNB Bank, at a regular meeting on February 25, declared a quarterly cash dividend of $0.38 per share. The cash dividend is payable on March 28, 2025, to shareholders of record March 14, 2025. QNB Corp. offers commercial and retail banking services through the twelve banking offices of its subsidiary, QNB Bank. QNB Corp.’s stock is traded in the over-the-counter market under the symbol “...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
MPAA MOTORCAR PARTS OF AMERICA INC.
GT GOODYEAR TIRE & RUBBER COMPANY
ETSY ETSY INC.
BFAM BRIGHT HORIZONS FAMILY SOLUTIONS INC.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
ROKU ROKU INC. CLASS A
10JF SEBATA HOLDINGS LTD
APP APPLOVIN CORP
KRT KARAT PACKAGING INC
TSE TRINSEO PLC
ASTS AST SPACEMOBILE INC
AUR AURORA INNOVATION INC
PHIN PHINIA INC
KLG_w WK KELLOGG CO
ATGL ALPHA TECHNOLOGY GROUP LTD
INLF INLIF LTD
MPLN MULTIPLAN CORPORATION
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on February 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 157,750 shares of Class A common stock and restricted stock units (RSUs) for 78,875 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ empl...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...
NTRA NATERA
MMSI MERIT MEDICAL SYSTEMS INC.
MDT MEDTRONIC PLC
LINC LINCOLN EDUCATIONAL SERVICES
FMS FRESENIUS MEDICAL CARE AG & CO. KGAA ADS
BMY BRISTOL-MYERS SQUIBB COMPANY
APEI AMERICAN PUBLIC EDUCATION
BSX. BELO SUN MINING CORP.
PEN PANORO ENERGY ASA
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
DGS. DIVIDEND GROWTH SPLIT
GH GUARDANT HEALTH
STRA STRATEGIC EDUCATION INC.
LRN STRIDE INC
LH LABCORP HOLDINGS INC
GSK GSK PLC
PROD PROSVETNO DELO AD ORD
Akero Therapeutics Announces Closing of Upsized Public Offering of Com...
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per sh...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Com...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at a public offering price of $48.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants ...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Akero Therapeutics Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero. In addition, Akero intends to grant the underwriters a 30-day option to purchase up to a...
Akero Therapeutics Reports Preliminary Topline Results Showing Statist...
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.